Exelixis (EXEL) Stock: Gaining On EU Regulatory Approval

Exelixis, Inc. (NASDAQ: EXEL) investors are cheering this morning as the stock is headed for the top. The gains are ultimately the result of an announcement that the company’s partner has received European Commission approval for a partnered product. Of course, this news is exciting investors who are pushing the stock up. Today, we’ll talk … Read more

Exelixis (EXEL) Stock: Climbing On CABOMETYX® News

Exelixis, Inc. (NASDAQ: EXEL) is having an overwhelmingly strong start to the trading session this morning, and for good reason. The company announced that the FDA has granted Priority Review surrounding one of the company’s pipeline treatments. Of course, this led to excitement among investors, sending the stock screaming for the top. As is normally … Read more

Exelixis (EXEL) Stock: Climbing On Exclusive Licensing Agreement!

Exelixis, Inc. (NASDAQ: EXEL) Exelixis is having an incredible day in the market today, and for good reason. The company announced that it has reached an exclusive licensing agreement for the commercialization and development of the company’s lead drug. Today, we’ll talk about the licensing agreement, how the market reacted to the news, and what … Read more